Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: Charles river - What They Never Told You

Charles River Laboratories Stock: Is Wall Street Bullish or Bearish?

Charles River Laboratories has continued to underperform the broader market over the past year, yet analysts remain moderately bullish on the stock’s prospects.

Barchart

Charles River Beat Expectations But Why Is The Stock Falling?

Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company’s strategic review.

Benzinga

Is Charles River Laboratories Stock Underperforming the Nasdaq?

Charles River Laboratories has significantly underperformed the Nasdaq Composite over the past year, yet analysts remain cautiously optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Charles River Laboratories Stock: Analyst Estimates & Ratings

Despite Charles River Laboratories’ weak performance relative to the broader market over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released second-quarter 2025 earnings.

Benzinga

Do Wall Street Analysts Like Charles River Laboratories Stock?

Charles River Laboratories stock has notably lagged behind the broader market over the past year, yet analysts remain moderately optimistic about the stock’s prospects.

Barchart

Charles River Laboratories Stock Outlook: Is Wall Street Bullish or Bearish?

Charles River Laboratories has lagged behind the broader market over the past year, with Wall Street analysts maintaining a cautious outlook on its future performance.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Charles River Laboratories Earnings Preview: What to Expect

Charles River Laboratories is poised to release its second-quarter earnings next month, and analysts expect a double-digit earnings dip.

Barchart

Vaccines are still tested with horseshoe crab blood. The industry is finally changing

The horseshoe crab bleeding industry is in transition. One biomedical company agreed to more oversight, and a regulatory group is paving the way for drug companies to use animal-free alternatives.

WEKU

Fate of 1,000 trafficked lab monkeys at center of US investigation in limbo

Long-tailed macaques at risk of being killed, or laundered or re-trafficked if returned to Cambodia, animal welfare groups say

The Guardian - US

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 4, 2022

Upgrades

Benzinga

Analyst Ratings for Charles River

Within the last quarter, Charles River (NYSE:CRL) has observed the following analyst ratings:

Benzinga

Charles River: Q1 Earnings Insights

Charles River (NYSE:CRL) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Preview: Charles River's Earnings

Charles River (NYSE:CRL) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Charles River will report an earnings per share (EPS) of $2.71.

Benzinga

Wells Fargo Maintains Overweight Rating for Charles River: Here's What You Need To Know

Wells Fargo has decided to maintain its Overweight rating of Charles River (NYSE:CRL) and lower its price target from $390.00 to $325.00. Shares of Charles River are trading down 7.96% over the last 24 hours, at $251.29 per share.

Benzinga

What 6 Analyst Ratings Have To Say About Charles River

Analysts have provided the following ratings for Charles River (NYSE:CRL) within the last quarter:

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 7, 2022

Upgrades

Benzinga

Charles River Buys Contract Vivarium Research Services Firm In $295M Deal

Charles River Laboratories International Inc (NYSE: CRL) has acquired Explora BioLabs Holdings Inc, a provider of contract vivarium research services,

Benzinga

Charles River Earnings Perspective: Return On Invested Capital

According to Benzinga Pro, during Q4, Charles River (NYSE:CRL) earned $139.83 million, a 32.97% increase from the preceding quarter. Charles River also posted a total of $905.05 million in sales, a 1.02% increase since Q3.

Benzinga

Charles River's Q4 Earnings Beats Street Expectation, Reaffirms FY22 Outlook

Charles River Laboratories International Inc's (NYSE: CRL)

Benzinga

Recap: Charles River Q4 Earnings

Charles River (NYSE:CRL) reported its Q4 earnings results on Wednesday, February 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.